Introduction Dabigatran is a direct oral anticoagulant (DOAC) used for the treatment of
several thrombotic conditions. To date, very few pharmacogenetic studies on dabigatran …

Dabigatran is a novel direct oral anticoagulant agent, whose plasma concentration is closely
related to bleeding risk. Genetic polymorphisms can affect the level of plasma dabigatran …

Background—Fixed-dose unmonitored treatment with dabigatran etexilate is effective and
has a favorable safety profile in the prevention of stroke in atrial fibrillation patients …

Essentials• Rivaroxaban and dabigatran are substrates of the P‐glycoprotein (P‐gp)
encoded by the ABCB1 gene.• We tested the effect of ABCB1 polymorphisms and of a P‐gp …

Introduction Dabigatran etexilate is given in fixed doses without coagulation monitoring for
the prevention of blood clots in at risk adults. A high inter-individual variability in blood …

The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by
intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its …

Objective To date, the influence of the carboxylesterase 1 (CES1) rs2244613 genotype on
the pharmacokinetics (PKs) and safety of dabigatran remains controversial. Hence, a …

Background Despite the well-studied safety profile of dabigatran, its interactions with genetic
polymorphism parameters are poorly understood, especially in patients with moderate …

This study was aimed to investigate the prevalence of the CES1 gene (c. 1168-33A> C,
rs2244613) polymorphism among 12 different ethnic groups living in Russia to provide a …

Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants
(DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics …